NAV

Peginterferon lambda-1a

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Peginterferon lambda-1a
Accession Number
DB14767
Description

Peginterferon lambda-1a is under investigation in clinical trial NCT01754974 (Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C).

Type
Biotech
Groups
Investigational
Synonyms
  • Peginterferon lambda-1a
External IDs
  • BMS-914143

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
0T0250N43U
CAS number
914617-98-4

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection1
3CompletedTreatmentHepatitis C Viral Infection1
3CompletedTreatmentHepatitis C Virus (HCV) Infection4
3WithdrawnTreatmentHepatitis C Virus (HCV) Infection1
2Active Not RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19)1
2CompletedTreatmentHepatitis B Virus (HBV)1
2CompletedTreatmentHepatitis C Viral Infection2
2CompletedTreatmentHepatitis D, Chronic1
2Enrolling by InvitationTreatmentCoronavirus Disease 2019 (COVID‑19) / COVID / COVID - 191
2Not Yet RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on May 20, 2019 08:26 / Updated on June 12, 2020 10:53

79